Gordon I.
About Gordon I.
Gordon I. serves as the Senior Medical Director at HI-Bio and is an Advisory Board Member at N8 Medical, where he also works as a Clinical Development and Medical Affairs Consultant. He has extensive experience in clinical development, having successfully launched a major immunosuppressive compound and developed recruitment strategies that exceeded projections in various transplant studies.
Current Role at HI-Bio
Gordon I. serves as the Senior Medical Director at HI-Bio, a role he has held since 2024. In this position, he is responsible for overseeing medical strategies and clinical development initiatives. His leadership contributes to the advancement of immunology research and the development of therapeutic solutions.
Advisory Role at N8 Medical
Since 2023, Gordon I. has been an Advisory Board Member at N8 Medical. He provides strategic insights and guidance to enhance the company's clinical development efforts. Additionally, he works as a Clinical Development and Medical Affairs Consultant, focusing on improving clinical trial processes and outcomes.
Professional Background in Clinical Development
Gordon I. has extensive experience in clinical development, having previously worked as Senior Medical Director at Talaris Therapeutics from 2021 to 2023. He also held the position of Medical Director for US Clinical Development in Hepatology and Transplantation at Novartis from 2019 to 2021. His background includes initiating over 50 investigator-initiated trials and achieving significant increases in clinical trial enrollment.
Educational Qualifications
Gordon I. earned his Doctor of Pharmacy degree from the University of North Carolina at Chapel Hill, where he studied from 1996 to 1998. He also holds a Bachelor of Science in Pharmacy from the same institution, completing his studies from 1991 to 1996. His education provides a strong foundation for his expertise in clinical development and medical affairs.
Achievements in Clinical Trials and Investments
Gordon I. has demonstrated success in clinical trial management, achieving a 30% increase in enrollment during the pandemic. He has also developed recruitment strategies that exceeded annual projections by 25% in studies related to NASH, kidney, and liver transplants. In addition to his clinical work, he has a 21% acquisition rate in a biotech investment portfolio as an accredited investor.